The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBTG Share News (BTG)

  • There is currently no data for BTG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Boston Scientific Gets Green Light For BTG Purchase At Court Meeting

Thu, 28th Feb 2019 18:01

LONDON (Alliance News) - BTG PLC on Thursday said a takeover offer by Bravo Bidco Ltd, a subsidiary of Boston Scientific Corp, was approved at the Court meeting and its own general meeting.

In November, US medical devices manufacturer agreed to acquire UK rival BTG for GBP3.3 billion. Under the terms of the acquisition agreement, Boston Scientific will pay 840 pence cash for each BTG share.

BTG shares closed 0.1% higher on Thursday at 833.00p each.

The acquisition has received merger control clearance in Germany, while the Taiwan Fair Trade Commission has terminated its investigation.

The FTSE 250 esoteric life sciences group said the transaction remains subject to the satisfaction or waiver of the remaining conditions, including the court's sanction.

BTG and Boston Scientific continue to anticipate that the acquisition will close around mid-2019.

More News
15 Jul 2015 05:18

AGM, EGM Calendar - Week Ahead

Read more
14 Jul 2015 14:59

AGM, EGM Calendar - Week Ahead

Read more
14 Jul 2015 05:18

AGM, EGM Calendar - Week Ahead

Read more
13 Jul 2015 15:07

AGM, EGM Calendar - Week Ahead

Read more
13 Jul 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
10 Jul 2015 16:11

AGM, EGM Calendar - Week Ahead

Read more
10 Jul 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
9 Jul 2015 15:21

AGM, EGM Calendar - Week Ahead

Read more
9 Jul 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
8 Jul 2015 15:20

AGM, EGM Calendar - Week Ahead

Read more
29 Jun 2015 14:51

Investec affirms 'buy' rating for BTG, confident about varicose vein treatment

Investec reiterated a 'buy' rating and price target of 647p for pharmaceuticals firm BTG after reappraising its key product Varithena. The bank said investors overreacted to concerns over BTG's earning profile, in particular the varicose vein treatment Varithena. "After interviewing physicians and

Read more
11 Jun 2015 10:26

WINNERS & LOSERS: RBS Rises, Royal Mail Sinks On UK Government Moves

Read more
11 Jun 2015 08:35

BROKER RATINGS SUMMARY: Liberum Raises Majestic Wine To Buy From Hold

Read more
11 Jun 2015 06:39

BTG Says First Patient Treated With TheraSphere In Singapore

Read more
27 May 2015 08:34

BROKER RATINGS SUMMARY: Brewin Dolphin Cut To Hold By Peel Hunt, Numis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.